drugset
drugset / Trial / NCT05861336

GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer

NCT05861336 ↗

Phase 2 Withdrawn Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NaSingle-groupOpen-labelTreatment

Summary

Single-arm, prospective, phase II study to evaluate safety and activity of an induction therapy with Gemcitabine (GEM) and nab-paclitaxel plus Losartan followed by Stereotactic Radiotherapy (SBRT) in patients affected by Locally Advanced Pancreatic Cancer (LAPC).

Timeline

Start
2023-06-14
Primary completion
2024-12-23
Completion
2024-12-23

Outcome

Outcome not reported

Stopped (Enrollment): “No patients enrolled”

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 1000 mg/m2 —
Subject Losartan Other / unclassified 50 mg Oral
Subject Nab-paclitaxel Small molecule 125 mg/m2 —

Indications

malignant pancreatic neoplasm